Fig. 4From: mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagyViability of SMMC-7721/gefitinib cells after incubation with different preparations for 24 h. Data are presented as mean ± SD (n = 3)Back to article page